Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

door Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H., Von Hoff, D. D.
Gepubliceerd in Ann Oncol (2016)

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

door Mahadevan, D., Chiorean, E.G., Harris, W.B., Von Hoff, D.D., Stejskal-Barnett, A., Qi, W., Anthony, S.P., Younger, A.E., Rensvold, D.M., Cordova, F., Shelton, C.F., Becker, M.D., Garlich, J.R., Durden, D.L., Ramanathan, R.K.
Gepubliceerd in 2012

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients...

door Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
Gepubliceerd in Ann Oncol (2016)